Revised Japan Prices Include Big Cuts For Gilead HCV Drugs
This article was originally published in PharmAsia News
Executive Summary
With policy surrounding the regular drug price revision in Japan next month finalized and a list of new tariff prices just released, it has become clear that Gilead is facing sizeable reimbursement reductions for its two big-selling hepatitis C drugs in the country.